Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Pak J Pharm Sci ; 31(6(Special)): 2869-2872, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30630801

ABSTRACT

To investigate the efficaciousness of breast-conserving therapy in connection with neoadjuvant chemotherapy on breast cancer. 68 patients, who were confirmed going down with breast cancer and hospitalized from June 2015 and June 2017, were sampled and divided into two groups using the random digit table, i.e. the observation group (n=34) and the control group (n=34). Patients in the observation group experienced breast-conserving therapy integrated with neoadjuvant chemotherapy, but those in the control group received the radical resection of breast cancer. Patients' condition in surgery, incidence of post-surgery complications as well as patient survivals were compared and coded. In the observation group, surgical duration, intraoperative bleeding amount, length of stay in hospital and incidence rate of post-surgery complications were all lower than the patients with the similar conditions in the control group with evident distinctions in statistics (p<0.05). In the observation group, survival ratios of one-to-five-year living patients were evidently higher than those in the control group. The distinctions owned evident significance in calculations (p<0.05). In comparison of the recurrence ratio of disease and the rate of distant metastasis between the observation group (5.88% and 8.82%) and the control group (11.76% and 8.82%), differences had no statistical significance (p>0.05). Before treatment, compared with the score of life quality in the two groups, no evident distinction in statistical exists (p>0.05), however, after that, the life quality in the observation group evidently outweighs the quality in the control group, which shows the distinctions in statistics (p<0.05). Breast-conserving therapy in combination with neoadjuvant chemotherapy shows promising clinical value in ameliorating the life quality, decreasing the mortality rate and the incidence of adverse reaction, which is expected to be applied in clinical practices as a kind of safe and effective method.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Docetaxel/therapeutic use , Epirubicin/therapeutic use , Mastectomy, Segmental/methods , Neoadjuvant Therapy/methods , Adult , Aged , Breast Neoplasms/secondary , China/epidemiology , Female , Humans , Middle Aged , Postoperative Complications/epidemiology , Quality of Life , Recurrence , Survival Analysis , Treatment Outcome
2.
Int J Pharm ; 500(1-2): 54-61, 2016 Mar 16.
Article in English | MEDLINE | ID: mdl-26748365

ABSTRACT

A liver-targeted drug delivery system (CX-EPNP) composed of PLGA/TPGS was prepared and characterized. The surface of nanoparticle was conjugated with LFC131 peptide to increase the specific interaction of carrier with CXCR4 overexpressing liver cancers to enhance the Epirubicin (EPI) delivery to tumors. The particles were nanosized with size than 150 nm and portrayed a sustained release kinetics suggesting its suitability for cancer targeting. The in vitro cell uptake results showed that the introduction of LFC131 to the nanoparticles could increase significantly the affinity to human hepatic carcinoma cells (HepG2) with approximately a 3-fold improvement in cellular uptake than non-targeted one. A specific receptor-mediated uptake was observed by confocal laser scanning microscopy. In addition, CX-EPNP showed remarkable cytotoxicity towards HepG2 cells, and could effectively inhibit tumor growth. The more significant EPI accumulation from CX-EPNP in the cancer cells gave rise to the enhanced EPI cytotoxicity and cell apoptosis. The CX-EPNP distributed mostly in the xenograft tumor after intravenous administration to mice and adequately remained in the blood for at least 24h. It seemed that CX-EPNP upon intravenous injection avoided rapid recognition by Kupffer cells and adequately remained in the blood. These findings suggest that CX-EPNP could effectively inhibit the growth of liver tumors in situ and could potentially reduce the systemic side effects. However, extensive investigation is still needed to assess the possible applications of the CX-EPNP in humans.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Epirubicin/administration & dosage , Nanoparticles/administration & dosage , Animals , Antibiotics, Antineoplastic/chemistry , Antibiotics, Antineoplastic/pharmacology , Antibiotics, Antineoplastic/therapeutic use , Cell Survival/drug effects , Drug Liberation , Epirubicin/chemistry , Epirubicin/pharmacology , Epirubicin/therapeutic use , Hep G2 Cells , Humans , Lactic Acid/chemistry , Liver Neoplasms/drug therapy , Liver Neoplasms/metabolism , Mice , Microscopy, Electron, Transmission , Nanoparticles/chemistry , Nanoparticles/therapeutic use , Nanoparticles/ultrastructure , Polyglycolic Acid/chemistry , Polylactic Acid-Polyglycolic Acid Copolymer , Treatment Outcome , Vitamin E/chemistry
3.
Int J Clin Exp Pathol ; 8(1): 368-73, 2015.
Article in English | MEDLINE | ID: mdl-25755724

ABSTRACT

OBJECTIVES: To investigate the crucial role of miR-26a in breast cancer and to validate whether miR-26a could regulate proliferation of breast cancer cells by targeting high mobility group AT-hook 1 (HMGA1). METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify the expression levels of miR-26a in breast cancer and adjacent non-cancerous breast tissues. MTT, cell migration and invasion assay were carried out to characterize the miR-26a function. Finally, to validate the target gene of miR-26a, luciferase reporter assay was employed, followed by RT-PCR and Western blot confirmation. RESULTS: Compared with normal tissues, a significant down-regulation of miR-26a expression was observed in breast cancer tissues (P=0.002). miR-26a suppresses MDA-MB-231 and Mcf-7 breast cancer cell lines proliferation and motility. The luciferase activity was significantly decreased after co-transfection with psiCHECK-2/HMGA1 3'-UTR and miR-26a mimics in comparison with control cells, and qRT-PCR and Western blotting analysis found that HMGA1 expression at the mRNA and protein levels decreased in the miR-26a mimic-treatment group relative to NC. MTT assay showed that down regulation of HMGA1 by siRNA could significantly enhance the tumor-suppressive effect of miR-26a (P < 0.05). CONCLUSIONS: The results of the present study indicate that miR-26a may be associated with human breast carcinogenesis, which inhibits tumor cell proliferation by targeting HMGA1.


Subject(s)
Breast Neoplasms/genetics , Cell Proliferation , Gene Expression Regulation, Neoplastic/genetics , HMGA Proteins/biosynthesis , MicroRNAs/genetics , Blotting, Western , Breast Neoplasms/pathology , Cell Proliferation/genetics , Female , Humans , Real-Time Polymerase Chain Reaction
4.
Oncol Res ; 20(12): 579-87, 2012.
Article in English | MEDLINE | ID: mdl-24139416

ABSTRACT

Metastasis is the most lethal attribute of human malignancy. High-level expression of survivin is involved in both carcinogenesis and angiogenesis in cancer. Previous studies indicate that a mutation of the threonine residue at position 34 (Thr34Ala) of survivin generates a dominant-negative mutant that induces apoptosis, inhibits angiogenesis, and suppresses highly metastatic breast carcinoma in mouse models. We investigated the efficacy of gene therapy with a survivin dominant-negative mutant and possible factors related to lymph node metastasis. The metastasis rate was compared between each group in order to find a survivin-targeted therapy against lymphangiogenesis in its earliest stages. We established lymph node metastasis models and treated animals with H22 tumors with Lip-mSurvivinT34A (Lip-mS), Lip-plasmid (Lip-P), or normal saline (NS). Eight days after the last dose, five randomly chosen mice from each group were sacrificed. We detected the apoptotic index, microvessel density (MVD), lymphatic microvessel density (LMVD), and the expression of VEGF-D with immunohistochemistry. After the remaining animals were sacrificed, we compared the tumor-infiltrated lymph nodes in each group. Administration of mSurvivinT34A plasmid complexed with cationic liposome (DOTAP/chol) resulted in the efficacious inhibition of tumor growth and lymph node metastasis within the mouse H22 tumor model. These responses were associated with tumor cell apoptosis, and angiogenesis and lymphangiogenesis inhibition. Our results suggested that Lip-mSurvivinT34A induced apoptosis and inhibited tumor angiogenesis and lymphangiogenesis, thus suppressing tumor growth and lymphatic metastasis. The mSurvivinT34A survivin mutant is a promising strategy of gene therapy to inhibit lymphatic metastasis.


Subject(s)
Genetic Therapy/methods , Inhibitor of Apoptosis Proteins/genetics , Plasmids/administration & dosage , Plasmids/genetics , Repressor Proteins/genetics , Animals , Apoptosis/genetics , Cell Line, Tumor , Female , Humans , Inhibitor of Apoptosis Proteins/biosynthesis , Liposomes/administration & dosage , Liver Neoplasms, Experimental/genetics , Liver Neoplasms, Experimental/metabolism , Liver Neoplasms, Experimental/pathology , Liver Neoplasms, Experimental/therapy , Lymphangiogenesis/genetics , Lymphatic Metastasis , Mice , Mice, Inbred BALB C , Mutation , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Neovascularization, Pathologic/therapy , Repressor Proteins/biosynthesis , Survivin
5.
J Cancer Res Clin Oncol ; 137(1): 19-28, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20217127

ABSTRACT

PURPOSE: Patients with localized prostate cancer can usually achieve initial response to conventional treatment. However, most of them will inevitably progress to advanced disease stage. There is a clear need to develop innovative and effective therapeutics for prostate cancer. Mouse survivin T34A (mS-T34A) is a phosphorylation-defective Thr34 → Ala dominant negative mutant, which represents a potential promising target for cancer gene therapy. This study was designed to determine whether mS-T34A plasmid encapsuled by DOTAP-chol liposome (Lip-mS) has the anti-tumor activity against prostate cancer, if so, to further investigate the possible mechanisms. METHODS: In vitro, TRAMP-C1 cells were transfected with Lip-mS and examined for apoptosis by PI staining and flow cytometric analysis. In vivo, subcutaneous prostate cancer models were established in C57BL/6 mice, which were randomly assigned into three groups to receive i.v. administrations of Lip-mS, pVITRO2-null plasmid complexed with DOTAP-chol liposome (Lip-null) or normal saline every 2 days for eight doses. Tumor volume was measured. Tumor tissues were inspected for apoptosis by TUNEL assay. Microvessel density (MVD) was determined by CD31 immunohistochemistry. Alginate-encapsulated tumor cell test was conducted to evaluate the treatment effect on angiogenesis. RESULTS: Administration of Lip-mS resulted in significant inhibition in the growth of mouse TRAMP-C1 tumors. The anti-tumor response was associated with increased tumor cell apoptosis and decreased microvessel density. CONCLUSIONS: The present study may be of importance in the exploration of the potential application of Lip-mS in the treatment of a broad spectrum of tumors.


Subject(s)
Inhibitor of Apoptosis Proteins/genetics , Mutation , Prostatic Neoplasms/therapy , Repressor Proteins/genetics , Animals , Cell Line, Tumor , Fatty Acids, Monounsaturated/administration & dosage , Genetic Therapy , Inhibitor of Apoptosis Proteins/therapeutic use , Liposomes/administration & dosage , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microscopy, Fluorescence , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Quaternary Ammonium Compounds/administration & dosage , Repressor Proteins/therapeutic use , Survivin
6.
Sichuan Da Xue Xue Bao Yi Xue Ban ; 41(3): 390-3, 2010 May.
Article in Chinese | MEDLINE | ID: mdl-20629305

ABSTRACT

OBJECTIVE: To investigate the effect of Survivin-T34A mutant on murine prostate cancer and its apoptosis-inducing efficacy in vivo and in vitro. METHODS: In vitro, prostate cancer cells TRAMP-C1 were transfected with Survivin-T34A plasmid encapsulated by cationic liposome. The apoptosis of TRAMP-C1 was evaluated with flow cytometry. C57BL/6 mice model with TRAMP-C1 prostate cancer was established. Twenty four male mice with TRAMP-C1 prostate cancers were divided randomly into three groups, which were intravenously injected with normal saline, empty vector PORF-9-null encapsulated by cationic liposome and Survivin-T34A plasmid encapsulated by cationic liposome respectively twice a week for eight doses. The size of tumors was measured and the tumor sections of each group were stained with TUNEL reagent for apoptosis detection. RESULTS: An apoptotic index of 46% of TRAMP-C1 transfected with Survivin-T34A plasmid encapsulated by cationic liposome was observed. The tumor volume of Survivin-T34A group of C57BL/6 mice with TRAMP-C1 prostate cancer was far smaller than those in the control groups (P < 0.05) and the tumors treated with Survivin-T34A showed significant increase of apoptosis compared with those of control groups (P < 0.05). CONCLUSION: Survivin-T34A mutant efficiently inhibits the growth of prostate cancer, which is based on the mechanism of Survivin-T34A mutant inducing apoptosis of tumor cells.


Subject(s)
Genetic Therapy/methods , Inhibitor of Apoptosis Proteins/genetics , Inhibitor of Apoptosis Proteins/pharmacology , Mutant Proteins/pharmacology , Prostatic Neoplasms/therapy , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/therapeutic use , Cell Line, Tumor , Male , Mice , Mice, Inbred C57BL , Prostatic Neoplasms/genetics , Random Allocation , Survivin
7.
J Exp Clin Cancer Res ; 29: 46, 2010 May 12.
Article in English | MEDLINE | ID: mdl-20462440

ABSTRACT

BACKGROUND: A high concentration of cisplatin (CDDP) induces apoptosis in many tumor cell lines. CDDP has been administered by infusion to avoid severe toxicity. Recently, it has been reported that changes in survivin expression or function may lead to tumor sensitization to chemical and physical agents. The aim of this study was to determine whether a dominant-negative mouse survivin mutant could enhance the anti-tumor activity of CDDP. METHODS: A plasmid encoding the phosphorylation-defective dominant-negative mouse survivin threonine 34-->alanine mutant (survivin T34A) complexed to a DOTAP-chol liposome (Lip-mS) was administered with or without CDDP in Lewis Lung Carcinoma (LLC) cells and in mice bearing LLC tumors, and the effects on apoptosis, tumor growth and angiogenesis were assessed. Data were analyzed using one-way analysis of variance(ANOVA), and a value of P < 0.05 was considered to be statistically significant. RESULTS: LLC cells treated with a combination of Lip-mS and CDDP displayed increased apoptosis compared with those treated with Lip-mS or CDDP alone. In mice bearing LLC tumors and treated with intravenous injections of Lip-mS and/or CDDP, combination treatment significantly reduced the mean tumor volume compared with either treatment alone. Moreover, the antitumor effect of Lip-mS combined with CDDP was greater than their anticipated additive effects. CONCLUSION: These data suggest that the dominant-negative survivin mutant, survivin T34A, sensitized LLC cells to chemotherapy of CDDP. The synergistic antitumor activity of the combination treatment may in part result from an increase in the apoptosis of tumor cells, inhibition of tumor angiogenesis and induction of a tumor-protective immune response.


Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Lewis Lung/drug therapy , Cisplatin/pharmacology , Liposomes/metabolism , Microtubule-Associated Proteins/metabolism , Mutation , Animals , Apoptosis , Combined Modality Therapy , Drug Synergism , Female , Genetic Therapy/methods , Inhibitor of Apoptosis Proteins , Mice , Mice, Inbred C57BL , Neovascularization, Pathologic , Survivin
8.
Oncol Rep ; 23(1): 97-103, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19956869

ABSTRACT

Radiosensitivity of tumors is due to a complex interaction of various factors, it has been reported that survivin also acts as a constitutive and inducible radioresistance factor in a panel of tumor cells and approaches designed to inhibit survivin expression or function may lead to tumor sensitisation to chemical and physical agents. Previously, we found that the plasmid encoding the phosphorylation-defective mouse survivin threonine 34-->alanine mutant complexed to DOTAP-chol liposome (Lip-mS) can suppress murine primary breast carcinoma. However, little is known regarding the biological effect of Lip-mS combined with radiation. The present study was designed to determine whether Lip-mS could enhance the anti-tumor activity of radiation. The Lewis Lung Carcinoma (LLC) cells treated with a combination of Lip-mS and radiation displayed apparently increased apoptosis compared with those treated with Lip-mS or radiation alone. Mice bearing LLC tumors were treated with intravenous injections of Lip-mS and radiation, the combined treatment significantly reduced mean tumor volume compared with either treatment alone. Moreover, the anti-tumor effect of Lip-mS combined with radiation was greater than their additive effect when compared with the expected effect of the combined treatment. These data suggest that inhibition of survivin using a dominant-negative mutant, survivin T34A, could sensitize LLC cells to radiation efficiently and the synergistic anti-tumor activity may in part result from increasing the apoptosis of tumor cells, inhibiting tumor angiogenesis and inducing a tumor-protective immune response in the combined treatment.


Subject(s)
Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/radiotherapy , Microtubule-Associated Proteins/genetics , Microtubule-Associated Proteins/physiology , Radiation Tolerance/genetics , Animals , Apoptosis , Cholesterol/pharmacology , Combined Modality Therapy/methods , Fatty Acids, Monounsaturated/pharmacology , Genes, Dominant , Inhibitor of Apoptosis Proteins , Liposomes/pharmacology , Mice , Mice, Inbred C57BL , Plasmids , Platelet Endothelial Cell Adhesion Molecule-1/biosynthesis , Quaternary Ammonium Compounds/pharmacology , Radiotherapy/methods , Repressor Proteins , Survivin , Tetrazolium Salts/pharmacology , Thiazoles/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...